---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-017230"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:41:10.257113+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allogene Q4 net loss $38.8M; cash runway into Q1 2028; cema-cel ALPHA3 interim April 2026

## Summary
- Q4 net loss $38.8M ($0.17/share); FY 2025 net loss $190.9M ($0.87/share).
- Cash, equivalents, investments $258.3M; runway extended into Q1 2028 via disciplined spending, $23.7M escrow return.
- Pivotal Phase 2 ALPHA3 trial of cema-cel in 1L LBCL; interim futility analysis (MRD clearance, safety) planned April 2026.
- Phase 1 RESOLUTION trial of ALLO-329 (CD19/CD70 CAR T) in autoimmune diseases; proof-of-concept data expected June 2026.
- ALLO-316 TRAVERSE trial in RCC completed Phase 1b enrollment; exploring partnering opportunities.

## SEC filing metadata
- accession: 0001628280-26-017230
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017230/0001628280-26-017230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000162828026017230/allo-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-017230
- JSON: https://secwatch.observer/filing/0001628280-26-017230.json
- Plain text: https://secwatch.observer/filing/0001628280-26-017230.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.